Antiatherosclerosis clinical trials using calcium antagonists

M. G. Bond, M. Mercuri, Fenwick T Nichols, S. A. Khoury, J. Flack, A. A. Carr

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

The antiatherogenic effect of calcium antagonists demonstrated in experimental animal models has stimulated clinical trials to determine whether they might beneficially affect the evolution of human atherosclerosis. Three clinical trials that assess the effects of calcium antagonists are reviewed here. The Montreal Heart Institute Study and the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT) study demonstrated that neither nicardipine nor nifedipine has a significant effect on established coronary artery lesions in patients with life-threatening diseases after 24 or 36 months of therapy, respectively. However, both studies showed a statistically significant effect on early stages of plaque evolution. Retrospective data analyses in the Montreal Study showed that nicardipine retarded the progression of minimal (≤20% stenosis) lesions, and the INTACT study prospectively demonstrated that nifedipine significantly (P = 0.034) reduced the number of new lesions. The ongoing Multicenter Isradipine/Diuretic Atherosclerosis Study (MIDAS) was designed specifically to compare the efficacy of isradipine and hydrochlorothiazide in retarding the progression of mild to moderate atherosclerosis in extracranial carotid arteries as assessed by B-mode ultrasonography. The results will be helpful in better understanding whether, and to what extent, isradipine beneficially affects atherosclerosis at the level of the arterial wall.

Original languageEnglish (US)
Pages (from-to)392-401
Number of pages10
JournalJournal of Vascular Medicine and Biology
Volume3
Issue number5
StatePublished - Dec 1 1991
Externally publishedYes

Fingerprint

Isradipine
Nifedipine
Atherosclerosis
Clinical Trials
Calcium
Nicardipine
Hydrochlorothiazide
Carotid Arteries
Diuretics
Ultrasonography
Coronary Vessels
Pathologic Constriction
Therapeutics
Animal Models

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Bond, M. G., Mercuri, M., Nichols, F. T., Khoury, S. A., Flack, J., & Carr, A. A. (1991). Antiatherosclerosis clinical trials using calcium antagonists. Journal of Vascular Medicine and Biology, 3(5), 392-401.

Antiatherosclerosis clinical trials using calcium antagonists. / Bond, M. G.; Mercuri, M.; Nichols, Fenwick T; Khoury, S. A.; Flack, J.; Carr, A. A.

In: Journal of Vascular Medicine and Biology, Vol. 3, No. 5, 01.12.1991, p. 392-401.

Research output: Contribution to journalReview article

Bond, MG, Mercuri, M, Nichols, FT, Khoury, SA, Flack, J & Carr, AA 1991, 'Antiatherosclerosis clinical trials using calcium antagonists', Journal of Vascular Medicine and Biology, vol. 3, no. 5, pp. 392-401.
Bond MG, Mercuri M, Nichols FT, Khoury SA, Flack J, Carr AA. Antiatherosclerosis clinical trials using calcium antagonists. Journal of Vascular Medicine and Biology. 1991 Dec 1;3(5):392-401.
Bond, M. G. ; Mercuri, M. ; Nichols, Fenwick T ; Khoury, S. A. ; Flack, J. ; Carr, A. A. / Antiatherosclerosis clinical trials using calcium antagonists. In: Journal of Vascular Medicine and Biology. 1991 ; Vol. 3, No. 5. pp. 392-401.
@article{67c76010aacf4d97b4098c158cae911d,
title = "Antiatherosclerosis clinical trials using calcium antagonists",
abstract = "The antiatherogenic effect of calcium antagonists demonstrated in experimental animal models has stimulated clinical trials to determine whether they might beneficially affect the evolution of human atherosclerosis. Three clinical trials that assess the effects of calcium antagonists are reviewed here. The Montreal Heart Institute Study and the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT) study demonstrated that neither nicardipine nor nifedipine has a significant effect on established coronary artery lesions in patients with life-threatening diseases after 24 or 36 months of therapy, respectively. However, both studies showed a statistically significant effect on early stages of plaque evolution. Retrospective data analyses in the Montreal Study showed that nicardipine retarded the progression of minimal (≤20{\%} stenosis) lesions, and the INTACT study prospectively demonstrated that nifedipine significantly (P = 0.034) reduced the number of new lesions. The ongoing Multicenter Isradipine/Diuretic Atherosclerosis Study (MIDAS) was designed specifically to compare the efficacy of isradipine and hydrochlorothiazide in retarding the progression of mild to moderate atherosclerosis in extracranial carotid arteries as assessed by B-mode ultrasonography. The results will be helpful in better understanding whether, and to what extent, isradipine beneficially affects atherosclerosis at the level of the arterial wall.",
author = "Bond, {M. G.} and M. Mercuri and Nichols, {Fenwick T} and Khoury, {S. A.} and J. Flack and Carr, {A. A.}",
year = "1991",
month = "12",
day = "1",
language = "English (US)",
volume = "3",
pages = "392--401",
journal = "Journal of Vascular Medicine and Biology",
issn = "1042-5268",
number = "5",

}

TY - JOUR

T1 - Antiatherosclerosis clinical trials using calcium antagonists

AU - Bond, M. G.

AU - Mercuri, M.

AU - Nichols, Fenwick T

AU - Khoury, S. A.

AU - Flack, J.

AU - Carr, A. A.

PY - 1991/12/1

Y1 - 1991/12/1

N2 - The antiatherogenic effect of calcium antagonists demonstrated in experimental animal models has stimulated clinical trials to determine whether they might beneficially affect the evolution of human atherosclerosis. Three clinical trials that assess the effects of calcium antagonists are reviewed here. The Montreal Heart Institute Study and the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT) study demonstrated that neither nicardipine nor nifedipine has a significant effect on established coronary artery lesions in patients with life-threatening diseases after 24 or 36 months of therapy, respectively. However, both studies showed a statistically significant effect on early stages of plaque evolution. Retrospective data analyses in the Montreal Study showed that nicardipine retarded the progression of minimal (≤20% stenosis) lesions, and the INTACT study prospectively demonstrated that nifedipine significantly (P = 0.034) reduced the number of new lesions. The ongoing Multicenter Isradipine/Diuretic Atherosclerosis Study (MIDAS) was designed specifically to compare the efficacy of isradipine and hydrochlorothiazide in retarding the progression of mild to moderate atherosclerosis in extracranial carotid arteries as assessed by B-mode ultrasonography. The results will be helpful in better understanding whether, and to what extent, isradipine beneficially affects atherosclerosis at the level of the arterial wall.

AB - The antiatherogenic effect of calcium antagonists demonstrated in experimental animal models has stimulated clinical trials to determine whether they might beneficially affect the evolution of human atherosclerosis. Three clinical trials that assess the effects of calcium antagonists are reviewed here. The Montreal Heart Institute Study and the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT) study demonstrated that neither nicardipine nor nifedipine has a significant effect on established coronary artery lesions in patients with life-threatening diseases after 24 or 36 months of therapy, respectively. However, both studies showed a statistically significant effect on early stages of plaque evolution. Retrospective data analyses in the Montreal Study showed that nicardipine retarded the progression of minimal (≤20% stenosis) lesions, and the INTACT study prospectively demonstrated that nifedipine significantly (P = 0.034) reduced the number of new lesions. The ongoing Multicenter Isradipine/Diuretic Atherosclerosis Study (MIDAS) was designed specifically to compare the efficacy of isradipine and hydrochlorothiazide in retarding the progression of mild to moderate atherosclerosis in extracranial carotid arteries as assessed by B-mode ultrasonography. The results will be helpful in better understanding whether, and to what extent, isradipine beneficially affects atherosclerosis at the level of the arterial wall.

UR - http://www.scopus.com/inward/record.url?scp=0026394914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026394914&partnerID=8YFLogxK

M3 - Review article

VL - 3

SP - 392

EP - 401

JO - Journal of Vascular Medicine and Biology

JF - Journal of Vascular Medicine and Biology

SN - 1042-5268

IS - 5

ER -